Samsung Bioepis Joins Biosimilar Lucentis Fray As It Unveils Phase III Plans
Samsung Bioepis has said it is preparing a Phase III trial with a proposed ranibizumab biosimilar, joining a number of players developing biosimilar versions of the ophthalmic use drug, which loses its first major patents in the next few years.
You may also be interested in...
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.
Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.